AstraZeneca and MedImmune, its global biologics research and development arm, will present updates from their early and late stage oncology pipelines at two major congresses this month. In total, 98 abstracts were accepted for the European Lung Cancer Conference (ELCC) in Geneva,11-14 April, and the American Association for Cancer Research (AACR) annual meeting in Chicago,14-18 April.
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the European Medicines Agency has validated for review the Marketing Authorisation Application (MAA) for Lynparza (olaparib).
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an investigational anti-CD22 recombinant immunotoxin and a potential new medicine for the treatment of adult patients with hairy cell leukaemia (HCL).
Patients will benefit from Lokelma’s rapid reduction and sustained control of potassium levels in the blood4,5
AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia. Hyperkalaemia is a serious condition characterised by elevated potassium levels in th
Michelle Werner har tillträtt som chef för AstraZenecas nordisk-baltiska marknadsbolag. Hon kommer närmast från en tjänst som chef för AstraZenecas verksamhet inom cancer i USA. Michelle har arbetat på AstraZeneca i snart tre år, och på ett antal andra läkemedelsföretag under totalt 20 år, bland annat i Frankrike och Storbritannien.
”Jag är verkligen glad över att ha fått möjligheten att leda d
AstraZeneca and MedImmune, today announced an updated timeline for the final analysis of the Phase III MYSTIC trial of Imfinzi (durvalumab). Based on current predictions, the final analysis of overall survival (OS) is now expected in the second half of 2018 (previously anticipated in the first half).
Real-world evidence study of more than 400,000 patients with type-2 diabetes, 74% of whom did not have a history of established cardiovascular disease, supports the association of CV benefits with use of Farxiga Latest analysis includes heart attack and stroke endpoints, longer follow-up period and six additional countries across Asia Pacific, the Middle East and North America
First European filing acceptance of a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in type-1 diabetes
10 abstracts including three late breakers presenting new Phase III data and landmark real-world evidence from Asia, Middle East and North America
AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules fromits early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio.
AstraZeneca and MSD’s new Lynparza tablet formulation recommended for maintenance therapy regardless of BRCA status
Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo)
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
Study reveals prolonging treatment with Brilinta 60mg after one year, reduces risk of major adverse cardiac events (MACE) by 19% and coronary death by 36%1 Builds on analysis2 showing 5-year ischaemic risk post-heart attack and benefits of long-term cardiovascular (CV) protection with Brilinta 60mg
Positiv utveckling avseende kommersiellt genomförande och kostnadsdisciplin; produktförsäljningen ökade under kvartalet. AstraZeneca står inför tillväxt i produktförsäljningen för helåret 2018
AstraZeneca today announced top-line results from the Phase III KRONOS trial that showed PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6µg, using Aerosphere Delivery Technology, in a pressurised metered-dose inhaler or pMDI) demonstrated a statistically significant improvement compared with dual combination therapies in six out of seven lung function primary endpoints.
AstraZeneca ranked 34th in Corporate Knights’ 14th annual Global 100 list of the most sustainable companies in the world
AstraZeneca identified as “biggest achiever” alongside Bank of America, and Coca Cola Enterprises Inc. (now Coca Cola European Partners) for 300% increase in renewable electricity in a single year
AstraZeneca has been recognised for its commitment to sustainability with tw
Lynparza is the first PARP inhibitor approved in Japan
Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza
Approval based on Phase III WINDWARD programme that demonstrated significant reductions in asthma exacerbations, improvements in lung functionand reductions inoral corticosteroid use from baseline, versus placebo
Fasenra is the first approved respiratory biologic with an 8-week maintenance dosing schedule
AstraZeneca and its global biologics research and development arm, MedImmune, today ann
AstraZeneca announced today the publication of a new analysis from an ongoing real-world quality registry that suggests the risk of experiencing a repeat heart attack (also known as a myocardial infarction or MI) from occlusions in non-stentedarteries is twice as high as the risk stemming from the initially stented artery following a first heart attack.